Taevas
Taevas maps, evaluates, and shortlists qualified distributors across 120+ markets so life sciences companies enter new territories with confidence, not guesswork.
Distributor Identification is a structured research and commercial intelligence service that locates, profiles, and evaluates potential distribution partners for life sciences products in target markets. It replaces ad hoc networking and trade-show cold outreach with a systematic, evidence-based process that surfaces the best-fit candidates from the full universe of qualified players.
Taevas combines primary research — including direct interviews with distributors, regulatory consultants, and in-country KOLs — with deep secondary intelligence on portfolio fit, financial health, regulatory track record, and channel reach. The result is a curated shortlist of vetted partners ranked against your specific commercial criteria, ready to enter structured negotiations.
Decision-grade distributor intelligence that shortens partner selection cycles from months to weeks.
We identify the full universe of active distributors in your target market, segmenting by therapeutic area, product category, channel type, and geographic reach.
Each candidate receives a detailed profile covering portfolio, revenue scale, regulatory capabilities, logistics infrastructure, and existing principal relationships.
Candidates are scored against your product requirements, target channels, regulatory needs, and strategic priorities to produce a ranked shortlist.
We assess each shortlisted distributor's appetite for new principal partnerships and flag any conflicts of interest or exclusivity constraints before you make first contact.
Every Taevas engagement is built on six interconnected research pillars that together produce a complete, actionable picture of your distribution landscape.
We conduct exhaustive desk research and primary outreach to map every relevant distributor operating in your target market. No candidate is excluded at this stage — breadth is prioritised so the shortlisting that follows is genuinely comprehensive.
We verify each distributor's regulatory track record, including import licences, GMP certifications, local registration experience, and pharmacovigilance infrastructure. Distributors that cannot meet your product's regulatory requirements are filtered out early, saving negotiation time.
We analyse each candidate's existing product portfolio to identify complementarity, competitive conflicts, and white-space alignment with your product. Channel coverage — hospital, pharmacy, specialist clinic, e-commerce — is mapped against your go-to-market model.
Revenue scale, growth trajectory, principal retention rates, and financial stability are assessed using available filings, industry databases, and primary interviews. This layer surfaces undercapitalised or overextended distributors before you invest in relationship-building.
We map each distributor's actual in-country reach — warehouse locations, cold-chain capability, last-mile logistics, and sub-distributor networks — against your target territories. Gaps in coverage are flagged so you can structure multi-distributor models where needed.
The final deliverable is a prioritised shortlist of three to eight distributors, each accompanied by a one-page profile, fit-score rationale, and recommended first-contact approach. Clients can move directly into structured partner conversations without additional groundwork.
A structured four-stage process that balances speed with rigour — typically complete in 4–6 weeks.
We align on objectives, geographies, therapy areas, and the specific business questions that need answering.
A 30–45 minute scoping call establishes the intelligence framework — ensuring every subsequent research hour is focused on decisions that matter.
Distributor landscapes vary dramatically across life sciences sectors — our research is calibrated to the commercial and regulatory realities of each.
From branded generics to biologics, we cover the full pharmaceutical value chain — clinical pipeline tracking, patent cliff analysis, and reimbursement modelling across regulated and emerging markets.
Taevas maintains active research networks and in-country intelligence across every commercially significant life sciences market globally.
India · China · Japan · South Korea · Australia · Indonesia · Thailand · Vietnam · Philippines
Germany · France · UK · Italy · Spain · Netherlands · Switzerland · Poland · Sweden
United States · Canada · Brazil · Mexico · Colombia · Argentina · Chile
UAE · Saudi Arabia · Turkey · Israel · Egypt · Qatar
South Africa · Nigeria · Kenya · Ethiopia · Morocco
Bangladesh · Sri Lanka · Pakistan · Nepal · Myanmar
Every Distributor Identification engagement includes a standardised set of eight deliverables, ensuring your team has everything needed to move from research to negotiation.
TAM/SAM/SOM with 5-year projections, segmented by product type, end user, and geography.
Profiling of top 10–15 players with pipeline, financials, positioning, and SWOT analysis.
Step-by-step approval guide, typical timelines, required dossiers, and local partner requirements.
Benchmark pricing across channels, reimbursement eligibility, and HTA decision landscape.
Prioritised strategy with recommended partnerships, channels, and launch sequencing.
Key opinion leaders, payer organisations, and the distributor ecosystem across target markets.
Interactive data visualisation summarising findings for C-suite and board presentations.
Post-delivery support to clarify findings, run scenario analyses, or refine recommendations.
Distributor Identification serves any life sciences organisation that needs to find, evaluate, or replace distribution partners in one or more international markets.
Evaluating new market entry, product launches in new geographies, or acquisitions requiring deep commercial due diligence.
Conducting commercial due diligence, validating market size assumptions, or assessing competitive moats before committing capital.
Seeking investor-grade market data to underpin fundraising narratives, identify first-mover opportunities, or prioritise expansion.
Understanding sector landscapes, benchmarking policy environments, and identifying foreign investment opportunities in health and life sciences.
Translating academic research into commercial potential assessments, technology transfer opportunities, and licensing strategy.
White-label intelligence support for strategy and management consulting firms advising clients across life sciences markets.
Our analysts work exclusively in pharma, medtech, and consumer health. Every report reflects deep domain expertise — not generic research methodology applied to healthcare.
We don’t just aggregate public data. Every engagement includes primary interviews with regulators, KOLs, payers, and channel partners — intelligence you can’t Google.
Our network spans India, Southeast Asia, MENA, and Sub-Saharan Africa — markets that generic firms cover superficially but where the greatest growth opportunities exist.
We write for decision-makers, not archives. Every report includes a clear recommendation. Our readout sessions are structured for board discussions, not just information transfer.
Rapid-response turnarounds of 2–4 weeks for focused engagements — without sacrificing the rigour of primary research and expert validation.
Our 30-day Q&A window, ongoing subscriptions, and retainer models mean we’re a long-term intelligence partner — not a one-off vendor.
“Taevas delivered a shortlist of seven qualified distributors across four Southeast Asian markets in under six weeks — a process that would have taken our team the better part of a year. Every candidate on that list was commercially credible and regulatory-ready.”
Distributor Identification is the starting point — pair it with these complementary Taevas services to build a complete market entry and partner management strategy.
From regulatory pathway mapping to full dossier preparation and submission management across global markets.
Shortlisting, evaluating, and connecting you with validated in-market partners, distributors, and licensing candidates.
Optimise launch pricing, reimbursement positioning, and access pathways to maximise commercial success from day one.
Scientific communication strategy, publication planning, and structured KOL engagement programmes for new market entrants.
Investor-grade commercial assessments for M&A, licensing deals, or fundraising — with rapid turnaround for live transactions.
Monthly or quarterly market monitoring — competitive signals, regulatory updates, and commercial developments as a managed service.
Tell us your target markets and product category and we will scope a Distributor Identification engagement that delivers a qualified, ranked shortlist in six weeks or less.